Federated Hermes Inc. Boosts Stake in Illumina, Inc. (NASDAQ:ILMN)

Federated Hermes Inc. grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 5.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 519,190 shares of the life sciences company's stock after purchasing an additional 25,605 shares during the period. Federated Hermes Inc. owned approximately 0.33% of Illumina worth $69,379,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Bleakley Financial Group LLC bought a new position in Illumina in the fourth quarter worth approximately $751,000. Zacks Investment Management bought a new position in shares of Illumina in the 3rd quarter worth $2,924,000. Van ECK Associates Corp grew its position in Illumina by 17.5% in the 4th quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company's stock valued at $20,347,000 after purchasing an additional 22,718 shares during the period. Strategic Financial Concepts LLC bought a new stake in Illumina during the 4th quarter valued at $1,464,000. Finally, Allworth Financial LP lifted its stake in shares of Illumina by 720.7% in the fourth quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company's stock valued at $1,001,000 after buying an additional 6,263 shares in the last quarter. Institutional investors own 89.42% of the company's stock.

Analyst Ratings Changes

ILMN has been the subject of several recent research reports. Citigroup decreased their target price on shares of Illumina from $90.00 to $85.00 and set a "neutral" rating for the company in a research report on Monday, April 7th. Royal Bank of Canada dropped their target price on Illumina from $128.00 to $112.00 and set an "outperform" rating on the stock in a report on Tuesday. Stephens reiterated an "overweight" rating and set a $156.00 price target on shares of Illumina in a report on Tuesday, March 11th. HSBC cut Illumina from a "buy" rating to a "hold" rating and set a $100.00 price objective on the stock. in a research note on Friday, February 28th. Finally, Robert W. Baird reduced their target price on shares of Illumina from $127.00 to $90.00 and set a "neutral" rating for the company in a research note on Wednesday, March 5th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $138.70.

Remove Ads

Illumina Stock Performance

Shares of Illumina stock traded up $3.52 during trading hours on Friday, reaching $74.78. The company had a trading volume of 3,040,860 shares, compared to its average volume of 2,265,473. The firm has a market cap of $11.85 billion, a PE ratio of -9.74, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38. Illumina, Inc. has a one year low of $68.70 and a one year high of $156.66. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The business has a fifty day simple moving average of $88.58 and a 200 day simple moving average of $122.32.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.